Bioproduction Market Scope And Analysis

Report Code : TIPRE00030322
Category : Life Sciences

Status : Published
No. of Pages : 209

Buy Now

Bioproduction Market Analysis, Scope, and Growth by 2030

Buy Now

Bioproduction Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 22.34 Billion
Market Size by 2030	US$ 63.39 Billion
Global CAGR (2022 - 2030)	13.9%
Historical Data	2020-2021
Forecast period	2023-2030
Segments Covered	By Product Biologics and Biosimilars Vaccines Cell and Gene Therapies Nucleic Acid Therapeutics By Application Rheumatoid Arthritis Hematological Disorders Cancer Diabetes Cardiovascular Diseases By Equipment Upstream Equipment Downstream Equipment Bioreactors Consumables and Accessories By End User Biopharmaceutical Companies Contract Manufacturing Organizations
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Thermo Fisher Scientific Inc Merck KGaA F Hoffmann La Roche Ltd Bio Rad Laboratories Inc Lonza Group AG bbi biotech GmbH Danaher Corp Sartorius AG FUJIFILM Irvine Scientific Inc

Industry Developments and Future Opportunities:

Various strategic developments by leading players operating in the bioproduction market are listed below:

In March 2023, Lonza declared that its intended cGMP clinical and commercial drug product production line in Visp (CH) has been completed. Customers with a range of production demands for drug products, for both clinical and commercial supply, will be served by the new line. Modern liquid and lyophilized vial filling isolator line for multiple modalities that satisfies the GMP Annex 1 requirement for the manufacture of sterile products is part of this 1,200 square meter cGMP facility. The line is already completely operating and has a cGMP license; in April 2023, the first client batches are scheduled to be filled.
In May 2022, FUJIFILM Irvine Scientific Inc, a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, announced the completion of its Innovation and Collaboration Center in Suzhou New District, China.
In December 2021, FUJIFILM Irvine Scientific Inc, a world leader in the development and manufacturer of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, announced the establishment of an Innovation and Collaboration Center in Suzhou New District, China. Through this new center, experts will collaborate with customers to design upstream cell culture processes that meet their biomanufacturing needs.
In March 2023, BiVACOR Inc’s Cormorant Asset Management and OneVentures, through OneVentures Healthcare Fund III, funded the company with US$ 18 million in capital. The funds will help the business hire important executives and support its ongoing R&D as well as early feasibility studies in human trials. Using this financial aid, the company would hire candidates for important roles, such as research and development professionals and the C-suite, as a part of its efforts to double its operations in size. The BiVACOR Inc further hopes to conduct an early feasibility study of its Total Artificial Heart for the first time in human subjects by the end of 2023.

Competitive Landscape and Key Companies:

Lonza Group AG, bbi-biotech GmbH, Danaher Corp, Sartorius AG, FUJIFILM Irvine Scientific Inc, Thermo Fisher Scientific Inc, Merck KGaA, F. Hoffmann-La Roche Ltd, and Bio-Rad Laboratories Inc are the prominent companies in the bioproduction market. These companies focus on new technologies, upgrading existing products, and geographic expansions to meet the growing consumer demand worldwide.